<div id="Tab4" class="Table">
<div class="Caption" lang="en"><div class="CaptionContent">
<span class="CaptionNumber">Table 4</span> <p class="SimplePara">Safety profile during the placebo-controlled period and the entire treatment period</p> </div></div>
<div class="u-scroll-horizontal"><table>
<colgroup>
<col class="tcol1 align-left">
<col class="tcol2 align-left">
<col class="tcol3 align-left">
<col class="tcol4 align-left">
<col class="tcol5 align-left">
<col class="tcol6 align-left">
<col class="tcol7 align-left">
</colgroup>
<thead>
<tr>
<th rowspan="2"> <p class="SimplePara">Variable</p> </th>
<th colspan="3"> <p class="SimplePara">Placebo-controlled period (16-week)</p> </th>
<th colspan="3"> <p class="SimplePara">Entire treatment period (104-week)<sup>a</sup></p> </th>
</tr>
<tr>
<th> <p class="SimplePara">Secukinumab 150 mg (<em class="EmphasisTypeItalic ">N</em> = 116)</p> </th>
<th> <p class="SimplePara">Secukinumab 150 mg</p> <p class="SimplePara">no load (<em class="EmphasisTypeItalic ">N</em> = 117)</p> </th>
<th> <p class="SimplePara">Placebo (<em class="EmphasisTypeItalic ">N</em> = 117)</p> </th>
<th> <p class="SimplePara">Secukinumab 150 mg (<em class="EmphasisTypeItalic ">N</em> = 116)</p> </th>
<th> <p class="SimplePara">Secukinumab 150 mg</p> <p class="SimplePara">no load (<em class="EmphasisTypeItalic ">N</em> = 117)</p> </th>
<th> <p class="SimplePara">Any secukinumab 150 mg (<em class="EmphasisTypeItalic ">N</em> = 346)<sup>b</sup></p> </th>
</tr>
</thead>
<tbody>
<tr>
<td> <p class="SimplePara">Exposure to study treatment—days, mean ± SD</p> </td>
<td> <p class="SimplePara">113.5 <strong class="EmphasisTypeBold ">±</strong> 7.03</p> </td>
<td> <p class="SimplePara">111.4 ± 11.96</p> </td>
<td> <p class="SimplePara">111.3 ± 12.97</p> </td>
<td> <p class="SimplePara">677.4 ± 146.34</p> </td>
<td> <p class="SimplePara">662.2 ± 170.31</p> </td>
<td> <p class="SimplePara">636.0 ± 159.98</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Any AE, <em class="EmphasisTypeItalic ">n</em>(%)</p> </td>
<td> <p class="SimplePara">72 (62.1)</p> </td>
<td> <p class="SimplePara">59 (50.4)</p> </td>
<td> <p class="SimplePara">64 (54.7)</p> </td>
<td> <p class="SimplePara">100 (86.2)</p> </td>
<td> <p class="SimplePara">98 (83.8)</p> </td>
<td> <p class="SimplePara">289 (83.5)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">SAE, <em class="EmphasisTypeItalic ">n</em>(%)</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">4 (3.4)</p> </td>
<td> <p class="SimplePara">18 (15.5)</p> </td>
<td> <p class="SimplePara">11 (9.4)</p> </td>
<td> <p class="SimplePara">43 (12.4)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Discontinued due to any AEs, <em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td> <p class="SimplePara">1 (0.9)</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">1 (0.9)</p> </td>
<td> <p class="SimplePara">9 (7.8)</p> </td>
<td> <p class="SimplePara">5 (4.3)</p> </td>
<td> <p class="SimplePara">20 (5.8)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Serious infection, <em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td> <p class="SimplePara">1 (0.9)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">4 (3.4)</p> </td>
<td> <p class="SimplePara">1 (0.9)</p> </td>
<td> <p class="SimplePara">8 (2.3)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Death<sup>c</sup>, <em class="EmphasisTypeItalic ">n </em>(%)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">4 (1.2)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Most common AEs<sup>d</sup></p> </td>
<td colspan="3"> <p class="SimplePara"><em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td colspan="3"> <p class="SimplePara"><em class="EmphasisTypeItalic ">n</em> (EAIR/100 patient-year)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Nasopharyngitis</p> </td>
<td> <p class="SimplePara">17 (14.7)</p> </td>
<td> <p class="SimplePara">11 (9.4)</p> </td>
<td> <p class="SimplePara">10 (8.5)</p> </td>
<td> <p class="SimplePara">32 (19.2)</p> </td>
<td> <p class="SimplePara">29 (16.7)</p> </td>
<td> <p class="SimplePara">80 (16.1)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> URTI</p> </td>
<td> <p class="SimplePara">4 (3.4)</p> </td>
<td> <p class="SimplePara">5 (4.3)</p> </td>
<td> <p class="SimplePara">6 (5.1)</p> </td>
<td> <p class="SimplePara">11 (5.5)</p> </td>
<td> <p class="SimplePara">17 (8.9)</p> </td>
<td> <p class="SimplePara">37 (6.7)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Diarrhea</p> </td>
<td> <p class="SimplePara">4 (3.4)</p> </td>
<td> <p class="SimplePara">6 (5.1)</p> </td>
<td> <p class="SimplePara">6 (5.1)</p> </td>
<td> <p class="SimplePara">9 (4.4)</p> </td>
<td> <p class="SimplePara">11 (5.5)</p> </td>
<td> <p class="SimplePara">28 (4.9)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Bronchitis</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">3 (2.6)</p> </td>
<td> <p class="SimplePara">1 (0.9)</p> </td>
<td> <p class="SimplePara">13 (6.4)</p> </td>
<td> <p class="SimplePara">8 (3.9)</p> </td>
<td> <p class="SimplePara">31 (5.4)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Hypertension</p> </td>
<td> <p class="SimplePara">5 (4.3)</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">9 (4.4)</p> </td>
<td> <p class="SimplePara">6 (3.0)</p> </td>
<td> <p class="SimplePara">18 (3.1)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> AS</p> </td>
<td> <p class="SimplePara">1 (0.9)</p> </td>
<td> <p class="SimplePara">3 (2.6)</p> </td>
<td> <p class="SimplePara">5 (4.3)</p> </td>
<td> <p class="SimplePara">12 (5.8)</p> </td>
<td> <p class="SimplePara">11 (5.5)</p> </td>
<td> <p class="SimplePara">29 (5.0)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Selected AEs of interest</p> </td>
<td colspan="3"> <p class="SimplePara"><em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td colspan="3"> <p class="SimplePara"><em class="EmphasisTypeItalic ">n</em> (EAIR/100 patient-year)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Candida infections</p> </td>
<td> <p class="SimplePara">3 (2.6)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">1 (0.9)</p> </td>
<td> <p class="SimplePara">4 (1.9)</p> </td>
<td> <p class="SimplePara">3 (1.4)</p> </td>
<td> <p class="SimplePara">8 (1.3)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Oral candidiasis</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">1 (0.9)</p> </td>
<td> <p class="SimplePara">2 (0.9)</p> </td>
<td> <p class="SimplePara">1 (0.5)</p> </td>
<td> <p class="SimplePara">3 (0.5)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Crohn’s disease</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">1 (0.9)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">1 (0.5)</p> </td>
<td> <p class="SimplePara">4 (0.7)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Neutropenia</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">1 (0.5)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">7 (1.2)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Uveitis</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">2 (0.9)</p> </td>
<td> <p class="SimplePara">2 (0.9)</p> </td>
<td> <p class="SimplePara">6 (1.0)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> MACE</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">2 (0.9)</p> </td>
<td> <p class="SimplePara">0 (0.0)</p> </td>
<td> <p class="SimplePara">4 (0.7)</p> </td>
</tr>
</tbody>
</table></div>
<div class="TableFooter"> <p class="SimplePara"><em class="EmphasisTypeItalic ">AE</em> adverse event, <em class="EmphasisTypeItalic ">AS</em> ankylosing spondylitis, <em class="EmphasisTypeItalic ">EAIR</em> exposure adjusted incidence rate, <em class="EmphasisTypeItalic ">MACE</em> major adverse cardiac events, <em class="EmphasisTypeItalic ">N</em> number of randomized patients, <em class="EmphasisTypeItalic ">SAE</em> serious AE, <em class="EmphasisTypeItalic ">SD</em> standard deviation, <em class="EmphasisTypeItalic ">URTI</em> upper respiratory tract infection</p> <p class="SimplePara"><sup>a</sup>The
 entire treatment period for safety data was from baseline through to 
the week 104 visit of each patient enrolled in this study</p> <p class="SimplePara"><sup>b</sup>Includes patients originally randomized to placebo who were switched to secukinumab at week 16 per the study design</p> <p class="SimplePara"><sup>c</sup>Three
 patients with a history of multiple baseline cardiac risk factors, who 
died during the entire treatment period (adjudicated as MACE): one case 
of myocardial infarction (day 159) in secukinumab 150 mg group, one
 case of myocardial ischemia (day 193) in placebo group switched to 
secukinumab at week 16, and one case of cardiac failure (day 398) in 
secukinumab 150 mg group. Another death case due to basal ganglia 
hemorrhage reported on day 716 in placebo group switched to secukinumab 
at week 16. These cases were considered to be unrelated to study 
medication</p> <p class="SimplePara"><sup>d</sup>AEs that occurred with 
an EAIR of at least 5.0 cases per 100 patient-years in either of the two
 secukinumab 150 mg groups or the Any secukinumab 150 mg group
 over the entire treatment period. Events listed according to preferred 
term in the Medical Dictionary for Regulatory Activities (MedDRA) 
version 17.0, sorted in descending order of EAIR in the Any secukinumab 
150 mg group for the entire treatment period</p> </div>
</div>